

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Zonana et al.

Patent No. 7,115,555

Issued: October 3, 2006

Application No. 09/729,658

Filed: December 4, 2000

Confirmation No. 3101

For: HYPOHIDROTIC ECTODERMAL
DYSPLASIA GENES AND PROTEINS

Examiner: Maria Marvich, Ph.D.

Art Unit: 1633

Attorney Reference No. 6907-55924-01

**FILED VIA EFS
ON AUGUST 16, 2007**

SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

In the Specification:

Column 4, line 21, (specification page 4, line 22), "(266→A)" should be
--(266G→A)--.

Column 6, lines 54-55 (specification page 7, line 7), "restores the normal phenotype" should be --the normal phenotype is restored--.

Column 8, line 16 (specification page 8, line 26), "restores the normal phenotype" should be --the normal phenotype is restored--.

Column 11, line 28 (specification page 12, line 8), "73:23744" should be
--73:237-44--.

Column 13, line 16 (specification page 14, line 6), “thereof Antibodies” should be --thereof. Antibodies--.

Column 13, line 22 (specification page 14, line 10), “D1” should be --DL--.

Column 13, lines 64-65 (specification page 14, line 34), “symptoms a disease” should be --symptoms of a disease--.

Column 14, line 6 (specification page 15, line 2), “symptoms a disease” should be --symptoms of a disease--.

Column 14, line 17 (specification page 15, line 8), “DL L,” should be --DL,--.

Column 14, line 24 (specification page 15, line 13), “EDA1-I” should be --EDA1-II--.

Column 16, line 49 (specification page 17, line 36), “disclosure are provides” should be --disclosure provides--.

Column 18, line 39 (specification page 19, line 33), “5 minute” should be --5 minutes--.

Column 19, line 2 (specification page 20, line 14), “3’ UR” should be --3’ UTR--.

Column 23, line 12, Table 1, in the first column under the heading “Family,” (specification page 24, line 32), “ED1018” should be --ED1018^b--.

Column 23, line 62 (specification page 25, lines 24-25), “Exon encodes” should be --Exon 5 encodes--.

Column 26, line 55 (specification page 28, line 34), “allowed hybridize” should be --allowed to hybridize--.

Column 33, Table 4, under the heading “IVS 4,” (specification page 35, Table 4), the ninth line of the nucleotide sequence,

“GGAAACCTCCGGGTTT7CAGTGTCCGGTTCTGTAGCAAGCTGAGGAAA” should be --GGAAACCTCCGGGTTTCAGTGTCCGGTTCTGTAGCAAGCTGAGGAAA--.

Column 37, Table 4, under the heading “Exon 12 (3 ‘UTR underlined),” (specification page 38, Table 4), the first line of the nucleotide sequence “GTCTTAGCCCCACGGAGCTGCCATTGATTGCCTCGAGAAGACTAGCCG” should be --GTCTTAGCCCCACGGAGCTGCCATTGATTGCCTCGAGAAGACTAGCCG--.

Column 37, Table 4, under the heading “Exon 12 (3 ‘UTR underlined),” (specification page 38, Table 4), the 21st line of the nucleotide sequence “TACCTATCCTTGAGGTACATCCATATTGTTACAGGCCTCCAGTCAATAAT” should be --TACCTATCCTTGAGGTACATCCATATTCTTACAGGCCTCCAGTCAATAAT--.

Column 41, Table 5, under the heading “Reverse Primer (5' - 3'),” (specification page 40, Table 5), the first line “GTAAGGGGCTCAGACCACT (75)” should be --GTAAGGGGCTCAGACCACT (75)--.

Column 43, line 53 (specification page 42, line 22), “151).” should be --151)).--.

Column 48, line 53 (specification page 47, line 33), “M2Ab” should be --M2mAb--.

Column 50, line 38 (specification page 49, line 28), “et at” should be --et al--.

Column 52, line 53 (specification page 52, line 5), “Hoffinan” should be --Hoffman--.

Column 52, line 54 (specification page 52, line 6), “Hoffinan” should be --Hoffman--.

Column 55, line 23 (specification page 54, line 33), “at least a 20,” should be --at least 20,--.

Column 58, line 49 (specification 58, line 17), “fill-length” should be --full-length--.

Column 60, line 18-19 (specification page 60, line 4), “gpt Mulligan” should be --gpt (Mulligan--.

Column 61, line 17 (specification page 61, line 6), “LTRS” should be --LTRs--.

Column 61, line 29 (specification page 61, line 14), “600 pg/ml” should be --600 µg/ml--.

Column 62, line 35 (specification page 62, line 22), “5-bromo4-chloro-3-indolyl” should be --5-bromo-4-chloro-3-indolyl--.

Column 65, line 56 (specification page 66, line 8), “reagent Myers” should be --reagent (Myers--.

Column 67, line 10 (specification page 67, line 23), “Eda-II” should be
--Eda1-II--.

Column 69, line 48 (specification page 70, line 14), “would be indicate” should be
--would indicate--.

Column 70 line 62-63 (specification page 71, line 26), “polymorphismis” should
be --polymorphisms--.

Column 73, line 24 (specification page 74, line 15), “EDA-1” should be
--EDA1-II--.

Column 74, line 4 (specification page 75, line 5), “(PSVL,” should be --(pSVL,--.

Column 74, line 5 (specification page 75, line 6), “(PBPV,” should be --(pBPV,--.

Column 75, line 21 (specification page 76, line 18), “a-actin” should be
-- α -actin--.

Column 76, line 31 (specification page 77, line 27), “termin” should be
--termini--.

Column 77, line 10 (specification page 78, line 17), “Papinoma” should be
--Papilloma--.

Column 81, line 3 (specification page 82, line 30), “complementarily” should be
--complementarity--.

Column 81, line 36 (specification page 83, line 13), “Leonetti et at.” should be
--Leonetti et al.,--.

Column 81, line 57 (specification page 83, line 26), “decreased of hair” should be
--decreased hair--.

Column 81, line 63 (specification page 83, line 31), “progression to of” should be
--progression of--.

Column 81, line 64 (specification page 83, line 31), “decreased of hair” should be
--decreased hair--.

Column 82, line 15 (specification page 84, line 5), “EDA-II” should be
--EDA1-II--.

In the Claims:

Column 171, line 64, claim 1 (5/9/2006 Amendment, page 2, claim 1),
“hypobidrotic” should be --hypohidrotic--.

Column 174, line 3, claim 9 (5/9/2006 Amendment, page 3, claim 74), “meted”
should be --method--.

A Certificate of Correction is attached to make formal notice of the errors in the
subject patent.

The fee of \$100.00 due under 37 C.F.R. § 1.20(a) is being paid concurrently
herewith via EFS.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,115,555

DATED : October 3, 2006

INVENTOR(S) : Zonana et al.

Page 1 of 4 Pages

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 4, line 21, "(266→A)" should be --(266G→A)--.

Column 6, lines 54-55, "restores the normal phenotype" should be --the normal phenotype is restored--.

Column 8, line 16, "restores the normal phenotype" should be --the normal phenotype is restored--.

Column 11, line 28, "73:23744" should be --73:237-44--.

Column 13, line 16, "thereof Antibodies" should be --thereof. Antibodies--.

Column 13, line 22, "D1" should be --DL--.

Column 13, lines 64-65, "symptoms a disease" should be --symptoms of a disease--.

Column 14, line 6, "symptoms a disease" should be --symptoms of a disease--.

Column 14, line 17, "DL L," should be --DL,--.

Column 14, line 24, "EDA1-I" should be --EDA1-II--.

Column 16, line 49 (specification page 17, line 36), "disclosure are provides" should be --disclosure provides--.

Column 18, line 39, "5 minute" should be --5 minutes--.

Column 19, line 2, "3' UR" should be --3' UTR--.

Column 23, line 12, Table 1, in the first column under the heading "Family," "ED1018" should be --ED1018^b--.

Column 23, line 62, "Exon encodes" should be --Exon 5 encodes--.

Column 26, line 55, "allowed hybridize" should be --allowed to hybridize--.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,115,555

No. of add'l copies 0
(@ .30 per page)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,115,555

DATED : October 3, 2006

INVENTOR(S) : Zonana et al.

Page 2 of 4 Pages

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33, Table 4, under the heading "IVS 4," the ninth line of the nucleotide sequence,
"GGAAACCTCCGGGTTT7CAGTGTCCGGTTCTGTAGCAAGCTGAGGAAA"
should be
--GGAAACCTCCGGGTTTCAGTGTCCGGTTCTGTAGCAAGCTGAGGAAA--.

Column 37, Table 4, under the heading "Exon 12 (3 'UTR underlined)," the first line of the nucleotide sequence
"GTCTTAGCCGACGGAGCTGCCATTGATTGCCTCGAGAAGACTAGCCG"
should be
--GTCTTAGCCCCACGGAGCTGCCATTGATTGCCTCGAGAAGACTAGCCG--.

Column 37, Table 4, under the heading "Exon 12 (3 'UTR underlined)," the 21st line of the nucleotide sequence
"TACCTATCCTTGAGGTCATCCATTGTTACAGGCCTCCAGTCAATAAT"
should be
--TACCTATCCTTGAGGTCATCCATTCTTACAGGCCTCCAGTCAATAAT--.

Column 41, Table 5, under the heading "Reverse Primer (5' - 3')," the first line
"GTAAGGGGCTCAGACCACT (75)" should be
--GTAAGGGGCTCAGACCACT (75)--.

Column 43, line 53, "151)." should be --151)).--.

Column 48, line 53, "M2Ab" should be --M2mAb--.

Column 50, line 38, "et al" should be --et al--.

Column 52, line 53, "Hoffinan" should be --Hoffman--.

Column 52, line 54, "Hoffinan" should be --Hoffman--.

Column 55, line 23, "at least a 20," should be --at least 20,--.

Column 58, line 49, "fill-length" should be --full-length--.

Column 60, line 18-19, "gpt Mulligan" should be --gpt (Mulligan--.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,115,555

No. of add'l copies 0
(@ .30 per page)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,115,555

DATED : October 3, 2006

INVENTOR(S) : Zonana et al.

Page 3 of 4 Pages

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 61, line 17, "LTRS" should be --LTRs--.

Column 61, line 29, "600 pg/ml" should be --600 µg/ml--.

Column 62, line 35, "5-bromo4-chloro-3-indolyl" should be --5-bromo-4-chloro-3-indolyl--.

Column 65, line 56, "reagent Myers" should be --reagent (Myers--.

Column 67, line 10, "Eda-II" should be --Eda1-II--.

Column 69, line 48, "would be indicate" should be --would indicate--.

Column 70 line 62-63, "polymorphismis" should be --polymorphisms--.

Column 73, line 24, "EDA-1" should be --EDA1-II--.

Column 74, line 4, "(PSVL," should be --(pSVL,--.

Column 74, line 5, "(PBPV," should be --(pBPV,--.

Column 75, line 21, "a-actin" should be --α-actin--.

Column 76, line 31, "termin" should be --termini--.

Column 77, line 10, "Papinoma" should be --Papilloma--.

Column 81, line 3, "complementarily" should be --complementarity--.

Column 81, line 36, "Leonetti et at." should be --Leonetti et al.,--.

Column 81, line 57, "decreased of hair" should be --decreased hair--.

Column 81, line 63, "progression to of" should be --progression of--.

Column 81, line 64, "decreased of hair" should be --decreased hair--.

Column 82, line 15, "EDA-II" should be --EDA1-II--.

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,115,555

No. of add'l copies 0
(@ .30 per page)

Page 3 of 4

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,115,555

DATED : October 3, 2006

INVENTOR(S) : Zonana et al.

Page 4 of 4 Pages

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

Column 171, line 64, claim 1, "hypobidrotic" should be --hypohidrotic--.

Column 174, line 3, claim 9, "meted" should be --method--.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. 7,115,555
No. of add'l copies 0
(@ .30 per page)

Page 4 of 4